Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis

Cancer Prevention Research

Volumn 5, Issue 2, 2012, Pages 197-204

  Wertheim, Betsy C ^a   Smith, Jeffrey W ^c   Fang, Changming ^c   Alberts, David S ^a,b   Lance, Peter ^a,b   Thompson, Patricia A ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; PLACEBO; URSODEOXYCHOLIC ACID;

AGED; ARTICLE; BILE ACID METABOLISM; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL ADENOMA; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOMA; AGED; CELL TRANSFORMATION, NEOPLASTIC; CHOLESTEROL 7-ALPHA-HYDROXYLASE; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; URSODEOXYCHOLIC ACID;

EID: 84863236869     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0320     Document Type: Article

References (39)

1. McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 1985;75:185-91. (Pubitemid 15229323)
2. Hill MJ, Aries VC. Faecal steroid composition and its relationship to cancer of the large bowel. J Pathol 1971;104:129-39.
3. Jensen OM, MacLennan R, Wahrendorf J. Diet, bowel function, fecal characteristics, and large bowel cancer in Denmark and Finland. Nutr Cancer 1982;4:5-19. (Pubitemid 13215690)
4. McKeigue PM, Adelstein AM, Marmot MG, Henly PJ, Owen RW, Hill MJ, et al. Diet and fecal steroid profile in a South Asian population with a low colon-cancer rate. Am J Clin Nutr 1989; 50:151-4. (Pubitemid 19195535)
5. Reddy BS, Hedges A, Laakso K, Wynder EL. Fecal constituents of a high-risk North American and a low-risk Finnish population for the development of large bowel cancer. Cancer Lett 1978;4:217-22. (Pubitemid 8325193)
6. Hill MJ, Drasar BS, Williams RE, Meade TW, Cox AG, Simpson JE, et al. Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet 1975;1:535-9.
7. Imray CH, Radley S, Davis A, Barker G, Hendrickse CW, Donovan IA, et al. Faecal unconjugated bile acids in patients with colorectal cancer or polyps. Gut 1992;33:1239-45.
8. Nordling MM, Glinghammar B, Karlsson PC, de Kok TM, Rafter JJ. Effects on cell proliferation, activator protein-1 and genotoxicity by fecal water from patients with colorectal adenomas. Scand J Gastroenterol 2003;38:549-55. (Pubitemid 36609863)
9. Tong JL, Ran ZH, Shen J, Fan GQ, Xiao SD. Association between fecal bile acids and colorectal cancer: a meta-analysis of observational studies. Yonsei Med J 2008;49:792-803.
10. Fracchia M, Galatola G, Sarotto I, Guraldo V, Perona M, Pera A, et al. Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas. Dig Liver Dis 2005; 37:509-14. (Pubitemid 44356058)
11. Ochsenkühn T, Bayerdörffer E, Meining A, Schinkel M, Thiede C, Nüssler V, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664-9. (Pubitemid 29169665)
12. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Paumgartner G. Variation of serum bile acids in patients with colorectal adenomas during a one-year follow-up. Digestion 1994;55:121-9. (Pubitemid 24051761)
13. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995;36:268-73.
14. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-51. (Pubitemid 23040017)
15. Brasitus TA. Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology 1995; 109:2036-8.
16. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994;54:5071-4.
17. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of egfr/raf-1/erk signaling in human colon cancer cells. J Nutr 2004;134:483-6. (Pubitemid 38141837)
18. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis 2001;22:35-41. (Pubitemid 32098141)
19. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95. (Pubitemid 32096335)
20. Pardi DS, Loftus EV Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124: 889-93. (Pubitemid 36389790)
21. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846-53. (Pubitemid 40909127)
22. Martinez-Augustin O, Sanchez de Medina F. Intestinal bile acid physiology and pathophysiology. World J Gastroenterol 2008;14:5630-40.
23. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443-63. (Pubitemid 34925641)
24. Wang J, Freeman DJ, Grundy SM, Levine DM, Guerra R, Cohen JC. Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest 1998;101:1283-91. (Pubitemid 28145244)
25. Couture P, Otvos JD, Cupples LA, Wilson PWF, Schaefer EJ, Ordovas JM. Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res 1999;40:1883-9. (Pubitemid 29477259)
26. Leníček M, Komárek V, Zimolová M, Kovár J, Jirsa M, Lukás M, et al. CYP7A1 promoter polymorphism -203A >Caffects bile salt synthesis rate in patients after ileal resection. J Lipid Res 2008;49:2664-7.
27. Hagiwara T, Kono S, Yin G, Toyomura K, Nagano J, Mizoue T, et al. Genetic polymorphism in cytochrome p450 7a1 and risk of colorectal cancer: the fukuoka colorectal cancer study. Cancer Res 2005;65: 2979-82. (Pubitemid 40490104)
28. Tabata S, Yin G, Ogawa S, Yamaguchi K, Mineshita M, Kono S. Genetic polymorphism of cholesterol 7α-hydroxylase (CYP7A1) and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci 2006; 97:406-10.
29. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.
30. Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. Common Variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 2010;29:629-37.
31. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89. (Pubitemid 32289743)
32. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9. (Pubitemid 37414228)
33. Hess LM, Krutzsch MF, Guillen J, Chow HHS, Einspahr J, Batta AK, et al. Results of a phase i multiple-dose clinical study of ursodeoxycholic acid. Cancer Epidemiol Biomarkers Prevent 2004;13:861-7. (Pubitemid 38737877)
34. Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006;290:G923-G32.
35. Lu Y, Feskens EJ, Boer JM, Muller M. The potential influence of genetic variants in genes along bile acid and bile metabolic pathway on blood cholesterol levels in the population. Atherosclerosis 2010;210:14-27.
36. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res 2010;3:604-10.
37. Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst 2010;102:1513-6.
38. Hisamuddin IM, Wehbi MA, Schmotzer B, Easley KA, Hylind LM, Giardiello FM, et al. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2005;14: 2366-9. (Pubitemid 41437838)
39. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-64. (Pubitemid 36760060)